



Better health  
for a better  
world™

Creating better health for a better world. That's what inspires Mylan in our mission to provide quality healthcare to the world's 7 billion people, one person at time.

Mylan is one of the world's leading global pharmaceutical companies. Our medicines include generic and brand name products in a variety of dosage forms, such as difficult-to-manufacture injectables, transdermal patches and HIV/AIDS antiretroviral (ARV) therapies. The company has innovative research and development capabilities and is one of the world's largest active pharmaceutical ingredient (API) manufacturers. Every one of our medications meets our one global quality standard regardless of where it is produced.

## Our Mission

At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:

- Innovate to satisfy unmet needs
- Make reliability and service excellence a habit
- Do what's right, not what's easy
- Impact the future through passionate global leadership

# 7B:1

## Fast Facts

**2014 Revenue:** \$7.72 billion

**Ticker:** NASDAQ: MYL

### Mylan Today

Information reflects Mylan's acquisition of Abbott's non-U.S. developed markets specialty and branded generics business.

**Global workforce:** approximately 30,000

**Products:** a global market portfolio of approximately 1,400 separate products

**Product submissions:** more than 3,400 new product submissions pending regulatory approval around the world

**Global presence:** sell products in approximately 145 countries and territories

**U.S. presence:** one out of every 13 prescriptions dispensed in the U.S. – brand name or generic – is a Mylan product

**Manufacturing presence:** operate 39 facilities in more than 10 countries


**Manufacturing capacity:** a total capacity of 58 billion oral solid dosages, 3,600 kiloliters of API, 500 million injectable units, 260 million patches and 15 million semisolid units

**R&D capabilities:** include an extensive range of dosage forms and delivery systems, including oral solid doses, transdermal patches, injectables, respiratory inhalants, topicals, soft gel capsules, nasal sprays, solutions, suspensions, ophthalmics, ARVs and APIs

**ARV access:** approximately 40% of people living with HIV/AIDS in the developing world who are receiving treatment depend on a Mylan product

**Notable:** member of S&P 500

## Operating Platform



## Our Evolution



## Key Access Initiatives

- Increase generic utilization
- Establish an effective generic biologics pathway
- Advance one global quality standard
- Enhance anaphylaxis awareness and expand access to epinephrine auto-injectors
- Stem the tide of HIV/AIDS

## Executive Management Team



**Robert J. Coury**  
Executive Chairman



**Heather Bresch**  
Chief Executive Officer



**Rajiv Malik**  
President



**John D. Sheehan**  
Chief Financial Officer

**Media Relations:**  
+1.724.514.1968  
communications@mylan.com

**Investor Relations:**  
+1.724.514.1813  
investor.relations@mylan.com

